Motor Neuron Disease and Risk of Cancer: A Population-Based Cohort Study in Denmark

Figures & data

Table 1 International Classification of Diseases 8th Revision and International Classification of Diseases 10th Revision Used to Identify Study Variables

	ICD-8	ICD-10
Amyotrophic lateral sclerosis and motor neuron disease	Motor neuron disease: 348 (amyotrophic lateral sclerosis 348.09, paralysis bulbaris progressive 348.19, paralysis spinalis progressive 348.20, atrophia musculorum progressiva alia 348.29, morbus neuronis motorii alius et non specificatus 348.99)	Motor neuron disease: G12.2 Amyotrophic lateral sclerosis: G12.2G
Cancer		C00-C96
Lung, bronchi and trachea		C33-C34
Brain and other nervous system cancers		C70-C72, D32, D42, D33, D352-D354, D43, D443- D445
Basal cell carcinoma		C44 restricted to ICD-O-3 morphology: 809
Prostate		C61
Malignant melanoma		C43
Breast		C50
Non-Hodgkin lymphoma		C82-C85, C90
Colorectal		C18-C19, C20
Lymphoid leukemia		C91
Urinary bladder		C67, D090, D303, D414 restricted to ICD-O-3 morphology: 812–813
Testicular cancer		C62
Salivary gland cancers		C07-C08

Abbreviations: ICD-8, The International Classification of Diseases 8th Revision; ICD-10, The International Classification of Diseases 10th Revision.

Table 2 Standardized Incidence Ratios for Selected Cancers Among Patients with Motor Neuron Diseases

Cancer site	<1 year of follow-up			1-5 years of follow-up			≥ 5 years of follow-up
	Observed	Expected	SIR (95% CI)	Observed	Expected	SIR (95% CI)	Observed	Expected	SIR (95% CI)
All	89	58.7	1.52 (1.22-1.87)	76	87.5	0.87 (0.68-1.09)	118	96.7	1.22 (1.01-1.46)
Colorectal	<5	NR	0.45 (0.09-1.32)	7	9.7	0.72 (0.29-1.49)	7	10.6	0.66 (0.27-1.37)
Lung, bronchi and trachea^a	16	6.9	2.30 (1.32-3.74)	<5	NR	0.39 (0.11-1.00)	13	10.9	1.19 (0.63-2.04)
Malignant melanoma^b	5	1.3	3.76 (1.22-8.76)	<5	NR	0.47 (0.01-2.64)	<5	NR	0.81 (0.10-2.93)
Breast	<5	NR	0.39 (0.05-1.42)	8	6.7	1.19 (0.51-2.34)	8	6.5	1.24 (0.53-2.44)
Prostate^a	5	6.0	0.83 (0.27-1.94)	<5	NR	0.41 (0.11-1.06)	13	11.7	1.11 (0.59-1.90)
Testicle^b	0	0.1	-	<5	NR	3.64 (0.09-20.29)	<5	NR	5.39 (0.65-19.46)
Urinary bladder	<5	NR	0.61 (0.07-2.22)	<5	NR	0.20 (0.01-1.12)	6	5.5	1.08 (0.40-2.36)
Brain and other nervous system	16	1.4	11.54 (6.59-18.75)	0	2.1	-	6	2.4	2.54 (0.93-5.54)
Non-Hodgkin malignant lymphoma	<5	NR	1.60 (0.33-4.68)	6	2.8	2.13 (0.78-4.65)	6	3.1	1.92 (0.71-4.19)
Lymphoid leukemia	<5	NR	2.89 (0.35-10.45)	<5	NR	2.91 (0.60-8.50)	<5	NR	2.64 (0.54-7.70)
Basal cell skin cancer	9	10.4	0.86 (0.39-1.64)	22	16.0	1.38 (0.86-2.08)	32	18.4	1.73 (1.19-2.45)
Other cancer sites combined	26	14.9	1.75 (1.14-2.56)	19	21.8	0.87 (0.53-1.36)	20	23.4	0.85 (0.52-1.32)

Notes: ^aCancers whose risk is reported to be decreased in MND (lung⁸ and prostate⁹). ^bCancers whose risk is reported to be increased in MND (salivary,^8,9 testicular,⁸ and melanoma⁸). There were no observed cases of salivary gland cancer during the follow-up.

Abbreviations: CI, confidence interval; NR, not reportable (to prevent back-calculation from SIR to comply with the Danish privacy regulations¹⁹); MND, motor neuron disease; SIR, standardized incidence ratio.

Gibson SB, Abbott D, Farnham JM, et al. Population-based risks for cancer in patients with ALS. Neurology. 2016;87(3):289–294. doi:10.1212/WNL.000000000000275727170569

 PubMed Web of Science ®Google Scholar

Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: record linkage studies. J Neurol Neurosurg Psychiatry. 2010;81(2):215–221. doi:10.1136/jnnp.2009.17546319726405

 PubMed Web of Science ®Google Scholar

Data Privacy Policy. Available from: https://www.dst.dk/ext/formid/datafortrolighed–pdf. Accessed 922, 2020.

 Google Scholar